Monoclonal antibodies for systemic lupus erythematosus (SLE)

Pharmaceuticals

Volumn 3, Issue 1, 2010, Pages 300-322

  Ponticelli, Claudio ^a   Moroni, Gabriella ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Lupus nephritis; Monoclonal antibodies; Rituximab; Systemic lupus erythematosus

Indexed keywords

ABT 325; ADALIMUMAB; AZATHIOPRINE; BELIMUMAB; BENLYSTA; BG 9588; BN 10; CD20 ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; COMPLEMENT INHIBITOR; CYCLOPHOSPHAMIDE; CYTOKINE ANTIBODY; ECULIZUMAB; EPRATUZUMAB; INFLIXIMAB; INOTUZUMAB OZOGAMICIN; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 18 ANTIBODY; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 6 ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IDEC 131; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; PLACEBO; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELTUZUMAB;

ANEMIA; ARTHROPATHY; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; BACKACHE; BACTERIAL INFECTION; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; CONTINUOUS INFUSION; COUGHING; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART INFARCTION; HEMATURIA; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOPATHOGENESIS; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; KERATITIS; KIDNEY DISEASE; LEUKOCYTE COUNT; LIVER DISEASE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOMA; MENINGITIS; MULTIPLE CYCLE TREATMENT; MYCOSIS; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OFF LABEL DRUG USE; PANCYTOPENIA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEINURIA; PRURITUS; PSORIASIS; RASH; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DEFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TUBERCULOSIS; URTICARIA;

EID: 77951948731     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3010300     Document Type: Review

References (116)

1. Austin, H.A.; Klippel, J.H.; Balow, J.E.; le Riche, N.G.; Steinberg, A.D.; Plotz, P.H.; Decker, J.L. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N. Engl. J. Med. 1986, 314, 614-619.
2. Houssiau, F.A.; Vasconcelos, C.; D'Cruz, D.; Sebastiani, G.D.; Garrido, E.; Ede, R.; Danieli, M.G.; Abramovicz, D.; Blockmans, D.; Mathieu, A.; Direskeneli, H.; Galeazzi, M.; Gül, A.; Levy, Y.; Petera, P.; Popovic, R.; Petrovic, R.; Sinico, R.A.; Cattaneo, R.; Font, J.; Depresseux, G.; Cosyns, J.P.; Cervera R. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002, 46, 2121-2131.
3. Appel, G.B.; Contreras, G.; Dooley, M.A.; Ginzler, E.M.; Isenberg, D.; Jayne, D.; Li, L.S.; Mysler, E.; Sánchez-Guerrero, J.; Solomons, N.; Wofsy, D.; Aspreva Lupus Management Study Group.: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 2009, 20, 1103-1112.
4. Moroni, G.; Doria, A.; Ponticelli, C. Cyclosporine (CsA) in lupus nephritis: assessing the evidence.Nephrol. Dial. Transplant 2009, 24, 15-20.
5. Cameron, J.S. Lupus nephritis. J. Am. Soc. Nephrol. 1999, 10, 413-424.
6. Moroni, G.; Quaglini, S.; Gallelli, B.; Banfi, G.; Messa, P.G.; Ponticelli C. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol. Dial. Transplant. 2007, 22, 2531-2539.
7. Isenberg D. Treating patients with lupus with B-cell depletion. Lupus. 2008, 17, 400-404.
8. Cvetkovic, R.S.; Perry, C.M. Rituximab. Drugs 2006, 66, 791-820.
9. Smith, M.R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003, 22, 7359-7368.
10. Waldman, M.; Appel, G.B. Update on the treatment of lupus nephritis. Kidney Int. 2006, 70, 1403-1412.
11. Ramos-Casals, M.; Soto, M.J.; Cuadrado, M.J.; Khamashta, M.A. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus 2009, 18, 767-776.
12. Ng, K.P.; Cambridge, G.; Leandro, M.J.; Edwards, J.C.; Ehrenstein, M.; Isenberg, D.A. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann. Rheum. Dis. 2007, 66, 1259-1262.
13. Lu, T.Y.; Ng, K.P.; Cambridge, G.; Leandro, M.J.; Edwards, J.C.; Ehrenstein, M; Isenberg, D.A. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 2009, 61, 482-487.
14. Vigna-Perez, M.; Hernández-Castro, B.; Paredes-Saharopulos, O.; Portales-Pérez, D.; Baranda, L.; Abud-Mendoza, C.; González-Amaro, R. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res. Ther. 2006, 8, R83.
15. Lindholm, C.; Börjesson-Asp, K.; Zendjanchi, K.; Sundqvist, A.C.; Tarkowski, A.; Bokarewa, M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J. Rheumatol. 2008, 35, 826-833.
16. Melander, C.; Sallée, M.; Trolliet, P.; Candon, S.; Belenfant, X.; Daugas, E.; Rémy, P.; Zarrouk, V.; Pillebout, E.; Jacquot, C.; Boffa, J.J.; Karras, A.; Masse, V.; Lesavre, P.; Elie, C.; Brocheriou, I.; Knebelmann, B.; Noël, L.H.; Fakhouri, F. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin. J. Am. Soc. Nephrol. 2009, 4, 579-587.
17. Boletis, J.N.; Marinaki, S.; Skalioti, C.; Lionaki, S.S.; Iniotaki, A.; Sfikakis, P.P. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol. Dial. Transplant 2009, 24, 2157-2160.
18. Carson, K.R.; Evens, A.M.; Richey, E.A.; Habermann, T.M.; Focosi, D.; Seymour J.F.; Laubach, J.; Bawn, S.D.; Gordon, L.I.; Winter, J.N.; Furman, R.R.; Vose, J.M.; Zelenetz, A.D.; Mamtani, R.; Raisch, D.W.; Dorshimer, G.W.; Rosen, S.T.; Muro, K.; Gottardi-Littell, N.R.; Talley, R.L.; Sartor, O.; Green, D.; Major, E.O.; Bennett, C.L. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009, 113, 4834-4840.
19. Molloy, E.S.; Calabrese, L.H. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun. Rev. 2008, 8, 144-146.
20. Nurmohamed, M.T. New Biologic Agents in the Treatment of Rheumatoid Arthritis. Do the benefits outweigh the risk? Drugs 2009, 69, 2035-2043.
21. Sfikakis, P.P.; Karali, V.; Lilakos, K.; Georgiou, G.; Panayioditis, P. Clonal expansion of B-cells in human systemic lupus erythematosus: evidence from studies before and after therapeutic B-cell depletion. Clin. Immunol. 2009, 132, 19-31.
22. Goldenberg, D.M.; Rossi, E.A.; Stein, R.; Cardillo, T.M.; Czuczman, M.S.; Hernandez-Ilizaliturri, F.J.; Hansen, H.J.; Chang, C.H. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 2009, 113, 1062-1067.
23. Poe, J.C.; Hasegawa, M.; Tedder, T.F. CD19, CD21, and CD22: multifaced response regulators of B lymphocyte signal transduction. Int. Rev. Imunol. 2001, 20, 739-762.
24. Dörner, T.; Kaufmann, J.; Wegener, W.A.; Teoh, N.; Goldenberg, D.M.; Burmester, G.R. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther. 2006, 8, R74.
25. Jacobi, A.M.; Goldenberg, D.M.; Hiepe, F.; Radbruch, A.; Burmester, G.R.; Dörner, T. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann. Rheum. Dis. 2008, 67, 450-457.
26. Goldenberg, D.M. Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev. Anticancer Ther. 2006, 6, 1341-1353.
27. Schneider, P. The role of APRIL and BAFF in lymphocyte activation. Curr. Opin. Immunol. 2005, 17, 282-289.
28. Stohl, W.; Metyas, S.; Tan, S.M.; Cheema, G.S.; Oamar, B.; Xu, D.; Roschke, V.; Wu, Y; Baker, K.P.; Hilbert, D.M. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003, 48, 3475-3486.
29. Furie, R.; Stohl, W.; Ginzler, E.M.; Becker, M.; Mishra, N.; Chatham, W.; Merrill, J.T.; Weinstein, A.; McCune, W.J.; Zhong, J.; Cai, W.; Freimuth, W. Belimumab Study Group. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res. Ther. 2008, 10, R109.
30. Ding, C. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Expert Opin. Biol. Ther. 2008, 8, 1805-1814.
31. Wallace, D.J.; Stohl, W.; Furie, R.A.; Lisse, J.R.; McKay, J.D.; Merrill, J.T.; Petri, M.A.; Ginzler, E.M.; Chatham, W.W.; McCune, W.J.; Fernandez, V.; Chevrier, M. R.; Zhong, Z.J.; Freimuth, W.W. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009, 61, 1168-1178.
32. Trial Watch. BLYS-targeted antibody shows promise in Phase III SLE trial. Nat. Rev. Drug Discov. 2009, 8, 688.
33. Heinrich, P.C.; Behrmann, I.; Müller-Newen, G.; Schaper, F.; Graeve, L. Interleukin-6 type cytokine signalling through the gp130(Jak/STAT pathway). Biochem. J. 1998, 334, 297-314.
34. Wan, S.; Zhou, Z.; Duan, B.; Morel, L. Direct B cell stimulation by dendritic cells in a mouse model of lupus. Arthritis Rheum. 2008, 58, 1741-1750.
35. Ogawa, Y.; Yoshinaga, T.; Nishikawa, M.; Takakura, Y. Unique cytokine production profile following stimulation with DNA in macrophages from NZB/W F1 mice. Biol. Pharm. Bull. 2008, 31, 1244-1249.
36. Nalbandian, A.; Crispín, J.C.; Tsokos, G.C. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin. Exp. Immunol. 2009, 157, 209-215.
37. Fransen, J.H.; Hilbrands, L.B.; Jacobs, C.W.; Adema, G.J.; Berden, J.H.; Van der Vlag, J. Both early and late apoptotic blebs are taken up by DC and induce IL-6 production. Autoimmunity 2009, 42, 325-327.
38. Aringer, M.; Smolen, J.S. Cytokine expression in lupus kidneys. Lupus 2005, 14, 13-18.
39. Chun, H.Y.; Chung, J.W.; Kim, H.A.; Yun, J.M.; Jeon, J.Y.; Ye, Y.M.; Kim, S.H.; Park, H.S.; Suh, C.H. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J. Clin. Immunol. 2007, 27, 461-466.
40. Li, Y.; Tucci, M.; Narain, S.; Barnes, E.V.; Sobel, E.S.; Segal, M.S.; Richards,H.B. Urinary biomarkers in lupus nephritis. Autoimmun. Rev. 2006, 5, 383-388.
41. De La Torre, M.; Urra, J.M; Blanco, J. Raised expression of cytokine receptor gp130 subunit on peripheral lymphocytes of patients with active lupus. A useful tool for monitoring the disease activity? Lupus 2009, 18, 216-222.
42. Mihara, M.; Takagi, N.; Takeda, Y.; Ohsugi, Y. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/NZW F1 mice. Clin. Exp. Immunol. 1998, 112, 397-402.
43. Liang, B.; Gardner, D.B.; Griswold, D.E.; Bugelski, P.J.; Song, X.Y. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 2006, 119, 296-305.
44. Ding, C.; Jones, G. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases. Rev. Recent Clin. Trials. 2006, 1, 193-200.
45. Illei, G.G.; Yarboro, C.; Shirota, Y.; Tockey, E.; Laptava, L.; Fleischer, T.; Balow, J.; Lipsky, P. Toclizumab (humanized anti-IL-6 receptor monoclonal antibody) in patients with systemic lupus erythematosus (SLE). Safety, tolerability and preliminary efficacy. Presented at ACR/ARHP Scientific Meeting, Washington, DC, USA, 11-15 November 2006; Abstract 500.
46. Jacob, C.O.; McDevitt, H.O. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature 1988, 331, 356-358.
47. Brennan, D.C.; Yui, M.A.; Wuthrich, R.P.; Kelley, V.E. Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. J. Immunol. 1989, 143, 3470-3475.
48. De Bandt, M. Lessons for lupus from tumour necrosis factor blockade. Lupus 2006, 15, 762-767.
49. De Bandt, M.; Sibilia, J.; Le Loët, X.; Prouzeau, S.; Fautrel, B.; Marcelli, C.; Boucquillard, E.; Siame, J.L.; Mariette, X. Club Rhumatismes et Inflammation.: Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: A French national survey. Arthritis Res. Ther. 2005, 7, R545-R551.
50. Aringer, M.; Graninger, W.B.; Steiner G.; Smolen, J.S. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 2004, 50, 3161-3169.
51. Principi, M.; Di Leo, A.; Ingrosso, M.; Pisani, A.; Marangi, S.; Amoruso, A.; Panella, C.; Francavilla, A.; Ierardi, E. Lupus nephritis improvement after anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatment for Crohn's disease: a case report. Immunopharmacol. Immunotoxicol. 2004, 26, 243-248.
52. Hayat, S.J.; Uppal, S.S.; Narayanan Nampoory, M.R.; Johny, K.V.; Gupta, R.; Al-Oun, M. Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis. Clin. Rheumatol. 2007, 26, 973-975.
53. Matsumura, R.; Umemiya, K.; Sugiyama, T.; Sueishi, M.; Umibe, T.; Ichikawa, K.; Yoshimura, M.: Study Group on Nephrology at the National Hospital Organization of Japan. Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients. Clin. Exp. Rheumatol. 2009, 27, 416-421.
54. Ideguchi, H.; Ohno, S.; Takase, K.; Hattori, H.; Kirino, Y.; Takeno, M.; Ishigatsubo, Y. Successful treatment of refractory lupus-associated haemophagocytic lymphohistiocytosis with infliximab. Rheumatology (Oxford) 2007, 46, 1621-1622.
55. Aringer, M.; Smolen, J.S. Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. Expert. Opin. Drug Saf. 2008, 7, 411-419.
56. Nurmohamed, M.T.; Dijkmans, B.A. Efficacy, tolerability and cost effectiveness of disease- modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 2005, 65, 661-694.
57. Nannini, C.; Cantini, F.; Niccoli, L.; Cassarà, E.; Salvarani, C.; Olivieri, I.; Lally, E.V. Single- center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? Arthritis Rheum. 2009, 61, 801-812.
58. Leombruno, J.P.; Einarson, T.R.; Keystone, E.C. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann. Rheum. Dis. 2009, 68, 1136-1145.
59. Colombel, J.F.; Sandborn, W.J.; Panaccione, R.; Robinson, A.M.; Lau, W.; Li, J.; Cardoso, A.T. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm. Bowel Dis. 2009, 15, 1308-1319.
60. Scheinfeld, N. Adalimumab: a review of side effects. Expert Opin. Drug Saf. 2005, 4, 637-641.
61. Hochberg, M.C.; Lebwohl, M.G.; Plevy, S.E.; Hobbs, K.F.; Yocum, D.E. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum. 2005, 34, 819-836.
62. van Kooten, C.; Banchereau J. CD40-CD40 ligand. J. Leukoc. Biol. 2000, 67, 2-17.
63. Desai-Mehta, A.; Lu, L.; Ramsey-Goldman, R.; Datta, S.K. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J. Clin. Invest. 1996, 97, 2063-2073.
64. Devi, B.S.; Van Noordin, S.; Krausz, T.; Davies, K.A. Peripheral blood lymphocytes in SLE- hyperexpression of CD154 on T and B lymphocytes and increased number of double negative T cells. J. Autoimmun. 1998, 11, 471-475.
65. Vakkalanka, R.K.; Woo, C.; Kirou, K.A.; Koshy, M.; Berger, D.; Crow, MK. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum. 1999, 42, 871-881.
66. Kato, K.; Santana-Sahagún, E.; Rassenti, L.Z.; Weisman, M.H.; Tamura, N.; Kobayashi, S.; Hashimoto, H.; Kipps, T.J. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J. Clin. Invest. 1999, 104, 947-955.
67. Early, G.S.; Zhao, W.; Burns, C.M. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J. Immunol. 1996, 157, 3159-3164.
68. Kalled, S.L.; Cutler, A.H.; Datta, S.K.; Thomas, D.W. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J. Immunol. 1998, 160, 2158-2165.
69. Kalled, S.L.; Cutler, A.H.; Ferrant, J.L. Long-term anti-CD154 dosing in nephritic mice is required to maintain survival and inhibit mediators of renal fibrosis. Lupus 2001, 10, 9-22.
70. Davis, J.C. Jr.; Totoritis, M.C.; Rosenberg, J.; Sklenar, T.A.; Wofsy, D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J. Rheumatol. 2001, 28, 95-101.
71. Huang, W.; Sinha, J.; Newman, J.; Reddy, B.; Budhai, L.; Furie, R.; Vaishnaw, A.; Davidson, A. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum. 2002, 46, 1554-1562.
72. Kalunian, K.C.; Davis, J.C. Jr.; Merrill, J.T.; Totoritis, M.C.; Wofsy, D. IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti- CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002, 46, 3251-3258.
73. Grammer, A.C.; Slota, R.; Fischer, R.; Gur, H.; Girschick, H.; Yarboro, C.; Illei, G.G.; Lipsky, P.E. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J. Clin. Invest. 2003, 112, 1506-1520.
74. Boumpas, D.T.; Furie, R.; Manzi, S.; Illei, G.G.; Wallace, D.J.; Balow, J.E.; Vaishnaw, A. BG9588 Lupus Nephritis Trial Group. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003, 48, 719-727.
75. Toubi, E.; Shoenfeld, Y. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity 2004, 37, 457-464.
76. Moore, K.W.; de Waal Malefyt, R.; Coffman, R.L.; O'Garra, A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 2001, 19, 683-765.
77. Dolff, S.; Abdulahad, W.H.; Bijl, M.; Kallenberg, C.G. Regulators of B-cell activity in SLE: a better target for treatment than B-cell depletion? Lupus 2009, 18, 575-580.
78. Llorente, L.; Zou, W.; Levy, Y.; Richaud-Patin, Y.; Wijdenes, J.; Alcocer-Varela, J.; Morel-Fourrier, B.; Brouet, J.C.; Alarcon-Segovia, D.; Galanaud, P.; Emilie, D. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J. Exp. Med. 1995, 181, 839-844.
79. Georgescu, L.; Vakkalanka, R.K.; Elkon, K.B.; Crow, M.K. Interleukin-10 promotes activation- induced cell death of SLE lymphocytes mediated by Fas ligand. J. Clin. Invest. 1997, 100, 2622-2633.
80. Blenman, K.R.; Duan, B.; Xu, Z.; Wan, S.; Atkinson, M.A.; Flotte, T.R.; Croker, B,P.; Morel, L. IL-10 regulation of lupus in the NZM2410 murine model. Lab. Invest. 2006, 86, 1136-1148.
81. Andersen, L.S.; Petersen, J.; Svenson, M.; Bendtzen, K.: Production of IL-1beta, IL-1 receptor antagonist and IL-10 by mononuclear cells from patients with SLE. Autoimmunity 1999, 30, 235-242.
82. Rizzo, R.; Hviid, T.V.; Govoni, M.; Padovan, M.; Rubini, M.; Melchiorri, L.; Stignani, M.; Carturan, S.; Grappa, M.T.; Fotinidi, M.; Ferretti, S.; Voss, A.; Laustrup, H.; Junker, P.; Trotta, F.; Baricordi, O.R. HLA-G genotype and HLA-G expression in systemic lupus erythematosus: HLA-G as a putative susceptibility gene in systemic lupus erythematosus. Tissue Antigens 2008, 71, 520-529.
83. Suh, C.H.; Kim, H.A. Cytokines and their receptors as biomarkers of systemic lupus erythematosus. Expert Rev. Mol. Diagn. 2008, 8, 189-198.
84. Mellor-Pita, S.; Citores, M.J.; Castejon, R.; Yebra-Bango, M.; Tutor-Ureta, P.; Rosado, S.; Andreu, J.L.; Vargas, J.A. Monocytes and T lymphocytes contribute to a predominance of interleukin 6 and interleukin 10 in systemic lupus erythematosus. Cytometry B Clin. Cytom. 2009, 76B, 261-270.
85. Mehrian, R.; Quismorio, F.P. Jr.; Strassmann, G.; Stimmler, M.M.; Horwitz, D.A.; Kitridou, R.C.; Gauderman, W.J.; Morrison, J.; Brautbar, C.; Jacob, C.O. Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum. 1998, 41, 596-602.
86. Mok, C.C.; Lanchbury, J.S.; Chan, D.W.; Lau, C.S. Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum. 1998, 41, 1090-1095.
87. Schotte, H.; Gaubitz, M.; Willeke, P.; Tidow, N.; Assmann, G.; Domschke, W.; Schlüter, B. Interleukin-10 promoter microsatellite polymorphisms in systemic lupus erythematosus: association with the anti-Sm immune response. Rheumatology (Oxford) 2004, 43, 1357-1363.
88. Lin, P.W.; Huang, C.M.; Huang, C.C.; Tsai, C.H.; Tsai, J.J.; Chang, C.P.; Tsai, F.J. The association of -627 interleukin-10 promoter polymorphism in Chinese patients with 2systemic lupus erythematosus. Clin. Rheumatol. 2007, 26, 298-301.
89. Chong, W.P.; Ip, W.K.; Wong, W.H.; Lau, C.S.; Chan, T.M.; Lau, Y.L. Association of interleukin-10 promoter polymorphisms with systemic lupus erythematosus. Genes Immun. 2004, 5, 484-492.
90. Rosado, S.; Rua-Figueroa, I.; Vargas, J.A.; Garcia-Laorden, M.I.; Losada-Fernandez, I.; Martin-Donaire, T.; Perez-Chacon, G.; Rodriguez-Gallego, C.; Naranjo-Hernandez, A.; Ojeda-Bruno, S.; Citores, M.J; Perez-Aciego, P. Interleukin-10 promoter polymorphisms in patients with systemic lupus erythematosus from the Canary Islands. Int. J. Immunogenet. 2008, 35, 235-242.
91. Nath, S.K.; Harley, J.B.; Lee, Y.H. Polymorphisms of complement receptor 1 and interleukin-10 genes and systemic lupus erythematosus: a meta-analysis. Hum. Genet. 2005, 118, 225-234.
92. Ishida, H.; Muchamuel, T.; Sakaguchi, S.; Andrade, S.; Menon, S.; Howard, M. Continuous administration of anti-interleukin-10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med. 1994, 179, 305-310.
93. Ravirajan, C.T.; Wang, Y.; Matis, L.A.; Papadaki, L.; Griffiths, M.H.; Latchman, D.S.; Isenberg, D.A. Effect of neutralizing antibodies to IL-10 and C5 on the renal damage caused by a pathogenic human anti-dsDNA antibody. Rheumatology (Oxford) 2004, 43, 442-447.
94. Llorente, L.; Richaud-Patin, Y.; García-Padilla, C.; Claret, E.; Jakez-Ocampo, J.; Cardiel, M.H.; Alcocer-Varela, J.; Grangeot-Keros, L.; Alarcón-Segovia, D.; Wijdenes, J.; Galanaud, P.; Emilie, D. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 2000, 43, 1790-1800.
95. Okamura, H.; Tsutsi, H.; Komatsu, T.; Yutsudo, M.; Hakura, A.; Tanimoto, T.; Torigoe, K.; Okura, T.; Nukada, Y.; Hattori, K. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995, 378, 88-91.
96. Nakanishi, K.; Yoshimoto, T.; Tsutsui, H.; Okamura, H. Interleukin-18 regulates both Th1 and Th2 responses. Annu. Rev. Immunol. 2001, 19, 423-474.
97. Dinarello, C.A. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol. 2007, 27, 98-114.
98. Liang, D.; Ma, W.; Yao, C.; Liu, H.; Chen, X. Imbalance of interleukin 18 and interleukin 18 binding protein in patients with lupus nephritis. Cell Mol. Immunol. 2006, 3, 303-306.
99. Calvani, N.; Tucci, M.; Richards, H.B.; Tartaglia,; Silvestris, F. Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18. Autoimmun. Rev. 2005, 4, 542-548.
100. Esfandiari, E.; McInnes, I.B.; Lindop, G.; Huang, F.P.; Field, M.; Komai-Koma, M.; Wei, X.; Liew, F.Y. A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease. J. Immunol. 2001, 167, 5338-5347.
101. Favilli, F.; Anzilotti; Martinelli, L.; Quattroni, P.; De Martino, S.; Pratesi, F.; Neumann, D.; Beermann, S.; Novick, D.; Dinarello, C.A.; Boraschi, D.; Migliorini, P. IL-18 activity in systemic lupus erythematosus. Ann. N.Y. Acad. Sci. 2009, 1173, 301-309.
102. Jelusic, M.; Lukic, I.K.; Batinic, D. Biological agents targeting interleukin-18. Drug News Perspect 2008, 20, 485-494.
103. Argiriadi, M.A.; Xiang, T.; Wu, C.; Ghayur, T.; Borhani, D.W. Unusual water-mediated antigenic recognition of the proinflammatory cytokine interleukin-18. J. Biol. Chem. 2009, 284, 24478-24489.
104. Bao, L.; Quigg, R.J. Complement in lupus nephritis: the good, the bad, and the unknown. Semin Nephrol. 2007, 27, 69-80.
105. Walport, M.J. Complement and systemic lupus erythematosus. Arthritis Res. 2002, 4 (Suppl. 3), S279-S293.
106. Moroni, G.; Trendelenburg, M.; Del Papa, N.; Quaglini, S.; Raschi, E.; Panzeri, P.; Testoni, C.; Tincani, A.; Banfi, G.; Balestrieri, G.; Schifferli, J.A.; Meroni, P.L; Ponticelli, C. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am. J. Kidney Dis. 2001, 37, 490-498.
107. Trendelenburg, M.; Lopez-Trascasa, M.; Potlukova, E.; Moll, S.; Regenass, S.; Frémeaux-Bacchi, V.; Martinez-Ara, J.; Jancova, E.; Picazo, M.L.; Honsova, E.; Tesar, V.; Sadallah, S.; Schifferli, J. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol. Dial. Transplant. 2006, 21, 3115-3121.
108. Kallenberg, C.G. Anti-C1q autoantibodies. Autoimmun. Rev. 2008, 7, 612-615.
109. Ricklin, D.; Lambris, J.D. Complement-target therapeutics. Nat. Biotechnol. 2007, 25, 1265-1267.
110. Parker C.J.; Kar S; Kirkpatrick P. Eculizumab. Nat. Rev. Drug Discov. 2007, 6, 515-625.
111. Hillmen, P.; Young, N.; Schubert, J.; Brodsky, R.; Socié, G.; Muus, P.; Röth, A.; Szer, J.; Elebute, M.; Nakamura, R.; Browne, P.; Risitano, A.; Hill, A.; Schrezenmeier, H.; Fu, C.; Maciejewski, J.; Rollins, S.; Mojcik, C.; Rother, R.; Luzzatto L. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 2006, 355, 1233-1243.
112. Emadi, A.; Brodsky R.A. Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria. Am. J. Hematol. 2009, 84, 699-701.
113. Davis, J. Eculizumab. Am. J. Health Syst. Pharm. 2008, 65, 1609-1615.
114. Robak E.; Robak T. Monoclonal antibodies in the treatment of systemic lupus erythematosus. Curr. Drug Targets 2009, 10, 26-37.
115. Bhat, P.; Radhakrishnan, J. B lymphocytes and lupus nephritis: New insights into pathogenesis and targeted therapies. Kidney Int. 2008, 73, 261-268.
116. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology Response Criteria for Proliferative and Membranous Renal Disease in Systemic Lupus Erythematosus Clinical Trials. Arthritis Rheum. 2006, 54, 421-432.